Skip to main content
    C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.59
    -0.24 (-0.83%)

    Market Cap: $2.26B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Celldex Therapeutics Inc (CLDX) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Celldex Therapeutics (CLDX) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Celldex Therapeutics reported EPS of -$0.96, above the -$1.02 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -4.36%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.06
    Range-$1.10 - -$0.97
    15 analysts
    Revenue Consensus
    $1.73M
    RangeN/A
    13 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.97
    Range-$1.14 - -$0.81
    5 analysts
    EPS Estimate DriftChange to current
    90d ago-$0.91-7.2%
    60d ago-$0.91-6.7%
    30d ago-$0.91-6.7%
    7d ago-$0.91-6.7%
    Current-$0.97
    Revenue Consensus
    $250.00K
    RangeN/A
    4 analysts

    Next Report

    CLDX has an expected report date of Feb 23, 2027.

    Earnings History

    Of the 40 quarters below that had an estimate, CLDX beat 23, missed 16 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2018, when EPS landed 315.84% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.96-$1.02-$1.07 - -$0.94+5.88%BeatN/A10N/ANov 5, 2026N/A
    Jun 30, 2026-$0.94-$1.04-$1.16 - -$0.92+9.62%BeatN/A104 up, 0 downAug 6, 2026$22000
    Mar 31, 2026-$1.18-$1.13-$1.32 - -$0.35-4.42%MissN/A10N/AMay 7, 2026$15000
    Dec 31, 2025-$1.22-$1.00-$1.13 - -$0.89-22.00%MissN/A120 up, 5 downFeb 25, 2026$120000
    Sep 30, 2025-$1.01-$0.89-$0.99 - -$0.86-13.48%MissN/A121 up, 4 downNov 10, 2025N/A
    Jun 30, 2025-$0.85-$0.86-$0.95 - -$0.76+1.16%BeatN/A101 up, 8 downAug 7, 2025$730000
    Mar 31, 2025-$0.81-$0.74-$0.92 - -$0.59-9.46%MissN/A101 up, 1 downMay 8, 2025$695000
    Dec 31, 2024-$0.71-$0.71-$0.87 - -$0.53+0.64%BeatN/A91 up, 3 downFeb 27, 2025$1.18M
    Sep 30, 2024-$0.64-$0.67-$0.75 - -$0.58+4.48%BeatN/A110 up, 0 downNov 6, 2024$3.19M
    Jun 30, 2024-$0.54-$0.59-$0.67 - -$0.51+8.47%BeatN/A90 up, 0 downAug 8, 2024$2.50M
    Mar 31, 2024-$0.56-$0.67-$0.75 - -$0.65+16.42%BeatN/A50 up, 0 downMay 6, 2024$156000
    Dec 31, 2023-$0.83-$0.74-$0.92 - -$0.49-12.16%MissN/A81 up, 0 downFeb 26, 2024$4.13M
    Sep 30, 2023-$0.81-$0.66-$0.75 - -$0.62-22.73%MissN/A70 up, 0 downNov 2, 2023$1.52M
    Jun 30, 2023-$0.65-$0.66-$0.72 - -$0.63+1.52%BeatN/A60 up, 0 downAug 8, 2023$268000
    Mar 31, 2023-$0.62-$0.60-$0.66 - -$0.60-3.33%MissN/A50 up, 0 downMay 4, 2023$967000
    Dec 31, 2022-$0.56-$0.59-$0.61 - -$0.56+5.08%BeatN/A60 up, 0 downFeb 28, 2023$1.61M
    Sep 30, 2022-$0.57-$0.57-$0.59 - -$0.550.00%In lineN/A60 up, 0 downNov 9, 2022$407000
    Jun 30, 2022-$0.58-$0.42N/A-38.10%MissN/AN/A0 up, 0 downAug 8, 2022$163000
    Mar 31, 2022-$0.50-$0.43-$0.49 - -$0.43-16.28%MissN/A50 up, 0 downMay 5, 2022$174000
    Dec 31, 2021-$0.43-$0.42-$0.47 - -$0.38-2.38%MissN/A6N/AFeb 28, 2022$333000
    Sep 30, 2021-$0.37-$0.35-$0.42 - -$0.32-5.71%MissN/A6N/ANov 9, 2021$153000
    Jun 30, 2021-$0.34-$0.40-$0.43 - -$0.37+15.00%BeatN/A4N/AAug 5, 2021$3.48M
    Mar 31, 2021-$0.42-$0.37N/A-13.51%MissN/AN/AN/AMay 6, 2021$685000
    Dec 31, 2020-$0.55-$0.37-$0.38 - -$0.35-48.65%MissN/A3N/AMar 29, 2021$3.79M
    Sep 30, 2020-$0.36-$0.38-$0.38 - -$0.34+5.26%BeatN/A2N/ANov 5, 2020$668000
    Jun 30, 2020-$0.57-$0.58-$0.77 - -$0.39+1.72%BeatN/A2N/AAug 6, 2020$236000
    Mar 31, 2020-$0.73-$0.72-$0.72 - -$0.70-1.39%MissN/A2N/AMay 6, 2020$2.73M
    Dec 31, 2019-$0.64-$0.90-$0.93 - -$0.87+28.89%BeatN/A2N/AMar 26, 2020$887000
    Sep 30, 2019-$0.75-$0.84-$0.84 - -$0.84+10.71%BeatN/A1N/ANov 12, 2019$546000
    Jun 30, 2019-$0.84-$1.17-$1.17 - -$1.17+28.21%BeatN/A1N/AAug 7, 2019$715000
    Mar 31, 2019-$1.40-$1.14-$1.14 - -$1.14-22.81%MissN/A1N/AMay 7, 2019$1.43M
    Dec 31, 2018-$0.81-$1.20-$1.20 - -$1.20+32.50%BeatN/A1N/AMar 7, 2019$1.77M
    Sep 30, 2018-$0.60-$2.55-$2.55 - -$1.05+76.47%BeatN/A3N/ANov 7, 2018$941000
    Jun 30, 2018-$1.65-$2.70-$2.70 - -$1.20+38.89%BeatN/A3N/AAug 8, 2018$2.76M
    Mar 31, 2018-$12.60-$3.03-$4.05 - -$1.65-315.84%MissN/A5N/AMay 10, 2018$4.07M
    Dec 31, 2017-$2.55-$3.71-$5.10 - -$2.85+31.27%BeatN/A7N/AMar 7, 2018$3.46M
    Sep 30, 2017-$3.00-$4.01-$4.50 - -$3.45+25.19%BeatN/A6N/ANov 7, 2017$3.92M
    Jun 30, 2017-$3.45-$4.17-$5.10 - -$3.45+17.27%BeatN/A7N/AAug 8, 2017$3.83M
    Mar 31, 2017-$4.20-$4.31N/A+2.55%BeatN/AN/AN/AMay 9, 2017$1.53M
    Dec 31, 2016-$4.50-$5.04N/A+10.71%BeatN/AN/AN/AMar 14, 2017$1.87M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.89, after -$2.45 the year before. It was -$18.90 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.89N/A
    Dec 31, 2024-$2.45N/A
    Dec 31, 2023-$2.91N/A
    Dec 31, 2022-$2.21N/A
    Dec 31, 2021-$1.56N/A
    Dec 31, 2020-$2.21N/A
    Dec 31, 2019-$3.63N/A
    Dec 31, 2018-$15.66N/A
    Dec 31, 2017-$13.20N/A
    Dec 31, 2016-$18.90N/A

    Frequently Asked Questions About CLDX

    When is Celldex Therapeutics's next earnings date?

    Celldex Therapeutics's next earnings report is expected for Feb 23, 2027.

    Did CLDX beat earnings estimates last quarter?

    Yes. Celldex Therapeutics reported EPS of -$0.96 for the quarter ended Sep 30, 2026, above the -$1.02 estimate, a 5.88% surprise.

    What EPS do analysts expect from CLDX next quarter?

    The consensus EPS estimate for Celldex Therapeutics for the quarter ending Dec 31, 2026 is -$1.06 from 15 analysts, with estimates from -$1.10 to -$0.97.

    How often does CLDX beat earnings estimates?

    Celldex Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.01%.